News and Announcements
Imugene Annual Update 2016; Clinical Sites in Asia Opened & New Substantial Shareholder
- Published January 18, 2017 5:24PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Imugene Ltd (ASX: IMU) is an immuno-oncology focused biopharmaceutical company, developing HER-Vaxx, a B Cell peptide vaccine for the treatment of gastric cancer. In no order of importance are listed Imugene’s achievements of 2016;
- A successful capital raising, in doing so bringing on a substantial shareholder in The Platinum Asset Management Fund.
- Opened our clinical sites in Asia and we look forward to enrolling the first cohort of patients.
- Progressed our mimotope discovery platform with the filing of four important patents.
Imugene are proud to have maintained and strengthened their already strong international intellectual property position. Also mentioning the progress made by their scientific team, both at home and abroad in Vienna.
Company Updates
BlackRock has named the next Economy. What this latest paper means for Private Market Investors.
BlackRock has put a name on something the smart money has been circling for two years. Its digital assets research team calls it the machine-native economy. The thesis fits in one line. AI is machine-native intelligence. Digital assets are machine-native money. Both are built on the same architecture, and they are converging into a single […]
Where’s the beef? Blackstone just answered the AI question.
In 1984, a fast food ad asked a question that became a catchphrase. Where’s the beef? Jon Gray, President of Blackstone, used that line this month in front of global LPs. It is the question every capital allocator is asking about AI. Trillions of dollars are going into chips, data centres and power. That is […]
The Best of Both Worlds: How Omnique Fund is Rewiring Real World Assets via Tokenisation
For decades, the playbook for Australia’s wholesale investors has remained relatively unchanged: pick between the slow-moving, illiquid reliability of tangible assets like property and gold, or chase the frictionless, high-velocity liquidity of public equity and digital markets. But as macroeconomic volatility spikes and a structural housing deficit reshapes private debt demand, sophisticated investors are demanding […]
Backed By Leading Investment Groups and Family Offices
